Major surgery within 4 weeks prior to randomization.Xx_NEWLINE_xXNo major surgery =< 4 weeks before pre-registrationXx_NEWLINE_xXMajor surgery within 2 weeks prior to randomization: patients must have recovered from any effects of any major surgeryXx_NEWLINE_xXPatients must NOT have radiotherapy, or major surgery or active drug therapy for pNET (SSA permitted) within 4 weeks prior to study treatment startXx_NEWLINE_xXPatients should not be randomized less than 3 weeks post-surgery but will not be acceptable for randomization more than 8 weeks post-surgeryXx_NEWLINE_xXMajor surgery must not have occurred within 2 weeks prior to enrollment and patients must have recovered from any effects of any major surgeryXx_NEWLINE_xXPatient has had surgery within 4 weeks prior to first doseXx_NEWLINE_xXMajor surgery within 4 weeksXx_NEWLINE_xXSubject has received surgery within the last four weeks.Xx_NEWLINE_xXPatients who have undergone major surgery within 4 weeks prior to registration are not eligibleXx_NEWLINE_xXMajor surgery, radiation therapy, or systemic anti-cancer therapy within 4 weeks of study treatment startXx_NEWLINE_xXMajor surgery other than diagnostic surgery, within 4 weeks prior to the first dose of test drug, minor surgery including diagnostic surgery within 2 weeks (14 days) excluding central IV port placements and needle aspirate/core biopsies. Radio frequency ablation or transcatheter arterial chemoembolization within 6 weeks prior to the first dose of test drug.Xx_NEWLINE_xX8. Major surgery within 4 weeks prior to first dose of TAB001 or still recovering from prior surgery;Xx_NEWLINE_xXHave a planned major surgery.Xx_NEWLINE_xXMajor surgery within 2 weeks of starting study treatment and patients must have recovered from any effects of any major surgeryXx_NEWLINE_xXMajor surgery within 3 weeks of scheduled C1D1 dosing.Xx_NEWLINE_xXMajor surgery or radiation therapy within 4 weeks prior to the first study doseXx_NEWLINE_xXPatients must have completed any major surgery or open biopsy >= 4 weeks from start of treatmentXx_NEWLINE_xXPatients, who have had a major surgery or significant traumatic injury within 4 weeks of start of study drug, patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia) or patients that may require major surgery during the course of the studyXx_NEWLINE_xXRecent major surgery within 4 weeks prior to first infusionXx_NEWLINE_xXMajor surgery within 4 weeks of study treatment startXx_NEWLINE_xXSubjects must have recovered from the effects of major surgery or significant traumatic injury at least 14 days prior to screening; no major surgery, other than diagnostic surgery, is allowed within 4 weeks prior to treatment in the studyXx_NEWLINE_xXPatients who are less than 4 weeks post-op after major surgeryXx_NEWLINE_xXSubject had major surgery within 4 weeks prior to randomization (kyphoplasty is not considered major surgery); subjects should have been fully recovered from any surgical related toxicities.Xx_NEWLINE_xXMajor surgery, other than diagnostic surgery, within 4 weeks prior to Cycle 1 Day 1, without complete recovery.Xx_NEWLINE_xXMajor surgery within 2 weeks prior to trial entry;Xx_NEWLINE_xXMajor surgery within 3 weeks prior to the start of study treatmentXx_NEWLINE_xXINCLUSION CRITERIA FOR SECOND-LINE THERAPY: Patients must have fully recovered from all effects of surgery; patients must have had at least two weeks after minor surgery and four weeks after major surgery before starting therapy; minor procedures requiring “twilight” sedation such as endoscopies or mediport placement may only require a 24-hour waiting period, but this must be discussed with an investigatorXx_NEWLINE_xXINCLUSION CRITERIA FOR THIRD-LINE THERAPY: Patients must have fully recovered from all effects of surgery; patients must have had at least two weeks after minor surgery and four weeks after major surgery before starting therapy; minor procedures requiring “twilight” sedation such as endoscopies or mediport placement may only require a 24-hour waiting period, but this must be discussed with an investigatorXx_NEWLINE_xXMajor surgery within 4 weeks of enrollmentXx_NEWLINE_xXMajor surgery, other than diagnostic surgery, within 2 weeks prior to Cycle 1 Day 1, without complete recovery.Xx_NEWLINE_xX?4 weeks since any major surgery and fully recovered.Xx_NEWLINE_xXHas had major surgery in the past 4 weeks.Xx_NEWLINE_xXMajor surgery within 4 weeks of first dose of study drugXx_NEWLINE_xXMajor surgery, anti-cancer therapy, or radiation therapy within 4 weeks of study treatmentXx_NEWLINE_xXMajor surgery within 3 weeks prior to first doseXx_NEWLINE_xXParticipants who have had major surgery within 2 weeks prior to starting study drug or has not recovered from major side effects (tumor biopsy is not considered as major surgery)Xx_NEWLINE_xXParticipant has not fully recovered from major surgery or significant traumatic injury prior the first dose of study drug or expects to have major surgery during the study period or within 6 months after the last dose of study drugXx_NEWLINE_xXMajor surgery within 3 weeks prior to first dose of study treatment, and patients must have recovered from the effects of surgeryXx_NEWLINE_xXMajor surgeryXx_NEWLINE_xXMajor surgery within 4 weeks before the first dose of study drugXx_NEWLINE_xXPatients, who have had a major surgery or significant traumatic injury within 4 weeks of start of study drug, patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia) or patients that may require major surgery during the course of the studyXx_NEWLINE_xXPatients who have had major surgery within 4 weeks prior to registration are not eligibleXx_NEWLINE_xXMajor surgery, other than diagnostic surgery, within 2 weeks prior to Cycle 1 Day 1, without complete recovery.Xx_NEWLINE_xXMajor surgery within 6 weeks of enrollmentXx_NEWLINE_xXActive infection requiring treatment with systemic anti-infectives or major surgery in prior 4 weeks.Xx_NEWLINE_xXHistory or major surgery within 4 weeks before the first dose of study treatment, or not recovered from prior surgeryXx_NEWLINE_xXMajor surgery within 2 months before planned first dose of study drugXx_NEWLINE_xXA minimum of 4 weeks from any major surgery prior to registrationXx_NEWLINE_xXPatients who have undergone major surgery =< 4 weeks prior to starting study drug or who have not recovered from side effects of such therapy prior to registrationXx_NEWLINE_xXMajor surgery within 3 weeks prior to first dose, prior peripheral stem cell transplant within 12 weeks of study enrollmentXx_NEWLINE_xXMajor surgery in the last three weeksXx_NEWLINE_xXAt least 2 weeks must have elapsed since undergoing major surgeryXx_NEWLINE_xXAt least 3 weeks from major surgeryXx_NEWLINE_xXMajor surgery or radiation within 4 weeks prior to study entryXx_NEWLINE_xXMajor surgery: 6 weeksXx_NEWLINE_xXMajor surgery within 3 weeks of starting the study or patient has not recovered from any effects of any major surgeryXx_NEWLINE_xXPrior major surgery within 12 weeks or prior major surgery from which the patient has not sufficiently recovered yetXx_NEWLINE_xXPHASE II EXCLUSION CRITERIA: Prior major surgery within 12 weeks or prior major surgery from which the patient has not sufficiently recovered yetXx_NEWLINE_xXMajor surgery within 4 weeks before the start of study therapy.Xx_NEWLINE_xXMajor surgery within 4 weeks before enrollmentXx_NEWLINE_xXMajor surgery, radiation therapy or systemic anti-cancer therapy within 2 weeks of starting study treatmentXx_NEWLINE_xXMajor surgery within 2 weeks of starting the study treatment, or not recovered to baseline status from the effects of surgery received > 2 weeks priorXx_NEWLINE_xXReasonably recovered from preceding major surgery as judged by the investigator or no major surgery within 4 weeks prior to the start of Day 1 treatmentXx_NEWLINE_xXAll major surgery including prior surgery to the brain within 3 weeks of commencement of study therapyXx_NEWLINE_xXMajor surgery, radiation, or treatment with any other investigational drug within 2 weeks of study treatmentXx_NEWLINE_xXPrior major treatment-related surgery completed at least 4 weeks prior to study drug administration;Xx_NEWLINE_xXMajor surgery within 4 weeks prior to the first study dose.Xx_NEWLINE_xXMajor surgery within 4 weeks prior to randomization.Xx_NEWLINE_xXPatients who underwent major surgery within 4 weeks before the planned day for the first treatmentXx_NEWLINE_xXMajor surgery without full recovery or within 3 weeks before planned randomization;Xx_NEWLINE_xXAt least 4 weeks since major surgery or radiation therapyXx_NEWLINE_xXPatients, who have had a major surgery or significant traumatic injury within 4 weeks of start of study drug, patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia) or patients that may require major surgery during the course of the studyXx_NEWLINE_xXMajor surgery within 4 weeks prior to randomization.Xx_NEWLINE_xXMajor surgery within 2 weeks of the first dose of study drugXx_NEWLINE_xXMajor surgery (excluding placement of vascular access) within 4 weeks of the first dose of study treatment.Xx_NEWLINE_xXHas had major surgery within 4 weeks before first study drug administrationXx_NEWLINE_xXMajor surgery within 4 weeks of first dose of study drugXx_NEWLINE_xXMajor surgery within 4 weeks before the start of study therapy.Xx_NEWLINE_xXHave had major surgery other than a minor outpatient procedure within 4 weeks prior to dose assignment or have not recovered from major side effects of the surgery if more than 4 weeks have elapsed since surgeryXx_NEWLINE_xXPatients who have had major surgery or significant traumatic injury within 4 weeks prior to registration, patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia), or patients that may require major surgery during the course of the studyXx_NEWLINE_xXMajor surgery within 4 weeks of first dose of study drugXx_NEWLINE_xXMajor surgery, other than diagnostic surgery, within 2 weeks prior to Cycle 1 Day 1, without complete recovery.Xx_NEWLINE_xXAny major surgery within 4 weeks prior to the first dose of study drug.Xx_NEWLINE_xXMajor surgery (e.g., intra-thoracic, intra-abdominal or intra-pelvic) within 4 weeks prior (2 weeks for resection of brain metastases) to starting INC280 or who have not recovered from side effects of such procedure; video-assisted thoracic surgery (VATS) and mediastinoscopy will not be counted as major surgery and patients can be enrolled in the study >= 1 week after the procedureXx_NEWLINE_xXMajor surgery within 4 weeks of the first dose of study treatmentXx_NEWLINE_xXAny major surgery, as determined by the Investigator, within 4 weeks of IMP administrationXx_NEWLINE_xXPatients who have undergone major surgery =< 4 weeks prior to starting study treatment or who have not recovered from side effects of such procedureXx_NEWLINE_xXMajor surgery within 4 weeks or minor surgery within 2 weeks before registration or scheduled for surgery during the projected course of the study; wounds will be completely healed prior to study entry and patients recovered from all toxicities from surgery; placement of vascular access device is not considered major or minor surgery in this regardXx_NEWLINE_xXPatients who have undergone major surgery < 4 weeks or minor surgery < 2 weeks prior to registration; wounds must be completely healed prior to study entry and patients recovered from all toxicities from surgery; placement of a vascular access device is not considered major or minor surgery in this regardXx_NEWLINE_xXMajor surgery within 4 weeks before starting study treatment or scheduled for surgery during the projected course of the studyXx_NEWLINE_xXHave had recent major surgery within a minimum of 4 weeks prior to starting study treatment, with the exception of surgical placement for vascular accessXx_NEWLINE_xXMajor surgery: ?2 weeksXx_NEWLINE_xXMajor surgery ? 2 weeks prior to starting CC-90002.Xx_NEWLINE_xXPatients who have had major surgery within 6 weeks prior to the first dose of study drug or have major surgery planned during the first 12 weeks after MT-3724 has finished.Xx_NEWLINE_xXRadiation therapy or major surgery within 4 weeks prior to first dose of study agentXx_NEWLINE_xXMajor surgery other than diagnostic surgery =< 4 weeks prior to registrationXx_NEWLINE_xXReasonably recovered from preceding major surgery as judged by the investigator or no major surgery within 4 weeks prior to the start of Day 1 treatmentXx_NEWLINE_xXPatients who have had major surgery must be fully recovered and >= 4 weeks post-operative prior to enrolling on studyXx_NEWLINE_xXPatients who have undergone major surgery within the 2 weeks prior to starting study treatment or who have not fully recovered from previous surgeryXx_NEWLINE_xXPatients who have had a major surgery or significant traumatic injury within 4 weeks of start of study drug, patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia) or patients that may require major surgery during the course of the studyXx_NEWLINE_xXPatients, who have had a major surgery or significant traumatic injury within 4 weeks of start of study drug, patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia) or patients that may require major surgery during the course of the studyXx_NEWLINE_xXPatient has undergone major surgery, other than diagnostic surgery (ie, surgery done to obtain a biopsy for diagnosis without removal of an organ), within 4 weeks prior to Day 1 of treatment in this study.Xx_NEWLINE_xXMajor surgery within 4 weeks prior to initiating treatment, excluding the placement of vascular accessXx_NEWLINE_xXPatients who have had major surgery within 3 weeks prior to enrollment are not eligible; procedures such as placement of a central vascular catheter, or limited tumor biopsy, are not considered major surgeryXx_NEWLINE_xXIncomplete recovery from major surgery within 4 weeks of enrollmentXx_NEWLINE_xXAt least 4 weeks from completion of major surgery and a healed surgical incisionXx_NEWLINE_xXMajor surgery within 4 weeks prior to cycle 1, other than for diagnosis.Xx_NEWLINE_xXSubjects must not have received chemotherapy, or undergone major surgery within 2 weeks and radiotherapy within 24 hours prior to enrollmentXx_NEWLINE_xXMajor surgery must have been completed ? 4 weeks prior to starting treatment day 1; patient must be sufficiently recovered and stable from surgery prior to treatment day 1Xx_NEWLINE_xXPatients that have had major surgery within 2 weeks of starting study treatment and patients must have recovered from any effects of any major surgeryXx_NEWLINE_xXNo major surgery within 4 weeks of first dose of sEPHB4Xx_NEWLINE_xXPatients who have received radiation therapy, radionuclide therapy or undergone major surgery within 4 weeks of enrollment; a biopsy will not preclude a patient from starting studyXx_NEWLINE_xXMajor surgery =< 4 weeks prior to registrationXx_NEWLINE_xXRecent major surgery (within 6 weeks prior to the start of cycle 1, day 1) other than for diagnosisXx_NEWLINE_xXMajor surgery within 2 weeks of starting study treatment and subjects must have recovered from any effects of any major surgery.Xx_NEWLINE_xXCRITERIA SPECIFIC FOR COHORT #2 (MCL): Major surgery within 4 weeks of first dose of study drugXx_NEWLINE_xXAt least 6 weeks after any major surgery including prior hepatic resection and recovery to =< grade 1 treatment-related toxicityXx_NEWLINE_xXMajor surgery within 4 weeks of first dose of study drugXx_NEWLINE_xXMajor surgery within 2 weeks prior to first dose of study drugXx_NEWLINE_xXMajor surgery within 4 weeks before the start of study therapy.Xx_NEWLINE_xXMajor surgery within 6 weeks prior to study day 1 (subjects must have completely recovered from any previous surgery prior to study day 1)Xx_NEWLINE_xXHistory of major surgery within 4 weeks prior to first dose on this studyXx_NEWLINE_xXMajor surgery (as defined by the Investigator): ?4 weeksXx_NEWLINE_xXMajor surgery within 4 weeks before the start of study therapy.Xx_NEWLINE_xXMajor surgery within 4 weeks of enrollment, or a wound that has not fully healedXx_NEWLINE_xXRecent major surgery (within 6 weeks prior to the start of study treatment) other than for diagnosisXx_NEWLINE_xXMajor surgery within 4 weeks of first dose of study medications. Minor procedures (e.g. port placement, endoscopy with intervention) within 2 weeks of first dose of study medications are allowedXx_NEWLINE_xXNo chemotherapy, radiotherapy, major surgery, or biologic therapy within 3 weeks of protocol treatmentXx_NEWLINE_xXKnown bleeding risk including serious hemorrhage or hemoptysis within the last 3 months; major surgery within the past 8 weeks or minor surgery within the past 4 weeksXx_NEWLINE_xXMajor surgery within 4 weeks of initiation of study drugXx_NEWLINE_xXMajor surgery within 4 weeks or radiation therapy within 14 days prior to study entryXx_NEWLINE_xXAt least 3 weeks between major surgery and planned start of study treatment; major incisions must have healedXx_NEWLINE_xXMajor surgery within 6 weeks of first dose of study medications; minor procedures (e.g. port placement, endoscopy with intervention) within 4 weeks of first dose of study medicationsXx_NEWLINE_xXMajor injuries and/or surgery within the past 4 weeks prior to start of study treatment with incomplete wound healing and/or planned surgery during the on-treatment study periodXx_NEWLINE_xXPatients who had undergone any major surgery within 4 weeks of study enrollmentXx_NEWLINE_xXMajor surgery within 4 weeks prior to enrollment (day 1)Xx_NEWLINE_xXMajor surgery within 4 weeks before screeningXx_NEWLINE_xXPatients who have undergone major surgery =< 2 weeks prior to starting study drug or who have not recovered from the side-effects of surgeryXx_NEWLINE_xXMajor surgery or a wound that has not fully healed within 4 weeks of enrollmentXx_NEWLINE_xXMajor surgery =< 4 weeks prior to registrationXx_NEWLINE_xXMajor surgery within 4 weeks prior to enrollmentXx_NEWLINE_xXMajor surgery within 2 weeks prior to registration or first dose of drugXx_NEWLINE_xXA minimum of 4 weeks from any major surgery prior to cycle 1 day 1Xx_NEWLINE_xXMajor surgery =< 4 weeks prior to registration (the surgical incision should be fully healed prior to drug administration or radiation therapy)Xx_NEWLINE_xXSurgery within 4 weeks of study drug administrationXx_NEWLINE_xXAny major surgery within 4 weeks, minor surgery within 2 weeks or other minor procedures requiring light sedation, such as endoscopies or mediport placement, within 48 hours prior to initiation of study treatmentXx_NEWLINE_xXMajor surgery (excluding placement of vascular access) within 4 weeks of the first dose of study treatment.Xx_NEWLINE_xXMajor surgery within 4 weeks of enrollmentXx_NEWLINE_xXHistory of recent major surgery within 6 weeks prior to the start of cycle 1, day 1 other than for diagnosisXx_NEWLINE_xXIf subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention and at least two weeks have to pass prior to starting therapyXx_NEWLINE_xX< 2 weeks since major surgery (i.e., laparotomy or thoracotomy)Xx_NEWLINE_xXPatients must have fully recovered from all effects of surgery; patients must have had at least two weeks after minor surgery and four weeks after major surgery before starting therapy; minor procedures requiring conscious sedation such as endoscopies or mediport placement may only require a 24-hour waiting period, but this must be discussed with an investigatorXx_NEWLINE_xXMajor surgery within 2 weeks prior to first dose of study drugXx_NEWLINE_xXMajor surgery performed within 4 weeks of study entryXx_NEWLINE_xXMajor surgery within 4 weeks of first dose of investigational productXx_NEWLINE_xXRecent major surgery within 4 weeks prior to starting study treatment. Minor surgery within 2 weeks of starting study treatment. Patients must be recovered from effects of surgeryXx_NEWLINE_xXRecent major surgery within 4 weeks prior to entry into the study (excluding the placement of vascular access and defunctioning stoma or any other surgical procedures not considered major by the investigator) that would prevent administration of study treatmentXx_NEWLINE_xXHas had major surgery within 4 weeks or minor surgery within 2 weeks prior to study day 1; subjects must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXMajor surgery within 2 weeks before day 1.Xx_NEWLINE_xXMajor surgery within 2 weeks of first dose of study drugXx_NEWLINE_xXMajor surgery (within 4 weeks prior to the start of cycle 1), other than for diagnosisXx_NEWLINE_xXMajor surgery within 4 weeks of initiation of study drugXx_NEWLINE_xXMajor surgery less than 6 weeks prior to the first dose of study drug; minor surgery less than 4 weeks prior to the first dose of study drugXx_NEWLINE_xXRecent major surgery within 4 weeks prior to starting study treatment, with the exception of surgical placement for vascular accessXx_NEWLINE_xXMajor surgery within 2 weeks of starting study treatment and patients must have recovered from any effects of any major surgeryXx_NEWLINE_xXMajor surgery within 4 weeks of first dose of study drugXx_NEWLINE_xXPrior major surgery within 2 weeks prior to the first dose of study drug or who has not recovered adequately from the toxicity and/or complications from the interventionXx_NEWLINE_xXMajor surgery other than diagnostic surgery =< 4 weeks prior to registrationXx_NEWLINE_xXNo major surgery within 4 weeks prior to enrollmentXx_NEWLINE_xXRecent major surgery (within 4 weeks prior to the start of Cycle 1), other than for diagnosisXx_NEWLINE_xXMajor surgery, other than diagnostic surgery, occurring 4 weeks prior to study entry; splenectomy will not be considered an exclusionary major surgeryXx_NEWLINE_xXSurgery: at least 2 weeks since undergoing any major surgery and must be recovered from effects of surgeryXx_NEWLINE_xXHad major surgery ? 4 weeks of C1D1Xx_NEWLINE_xXMajor surgery =< 4 weeks prior to registrationXx_NEWLINE_xXMajor surgery (requiring general anesthesia) within 2 weeks prior to initiation of therapyXx_NEWLINE_xXMajor surgery within 4 weeks of first dose of study drugXx_NEWLINE_xXRecent major surgery (within 6 weeks prior to the start of study treatment) other than for diagnosisXx_NEWLINE_xXPatients must have fully recovered from all effects of surgery; patients must have had at least two weeks after minor surgery and four weeks after major surgery before starting therapy; minor procedures requiring “Twilight” sedation such as endoscopies or mediport placement may only require a 24-hour waiting period, but this must be discussed with an investigatorXx_NEWLINE_xXAny major surgery within 4 weeks or a diagnostic procedure (eg incision, needle biopsy) within 1 day of study drug administrationXx_NEWLINE_xXMajor surgery within 4 weeks before starting study treatment or scheduled for surgery during the projected course of the studyXx_NEWLINE_xXMajor surgery within 4 weeks prior to day 1 of the study or who have not recovered from prior surgeryXx_NEWLINE_xXMajor surgery within 3 weeks prior to first doseXx_NEWLINE_xXA minimum of 4 weeks from any major surgery prior to registrationXx_NEWLINE_xXMajor surgery (major according to the Investigator's assessment) performed within 12 weeks prior to first trial treatment or planned within 12 months after screening, e.g.,hip replacementXx_NEWLINE_xXPatients who have had major surgery must be fully recovered and require a recovery period of >= 4 weeks prior to enrolling on studyXx_NEWLINE_xXMajor surgery within 4 weeks of first dose of study drugXx_NEWLINE_xXMajor surgery within 4 weeks before first dose of study drugXx_NEWLINE_xXReceived major surgery, radiotherapy, or immunotherapy within 4 weeks of GSK2879552 administrationXx_NEWLINE_xXMajor surgery or a wound that has not fully healed within 4 weeks of enrollmentXx_NEWLINE_xXRecent major surgery within 4 weeks prior to entry into the study (excluding the placement of vascular access) which would prevent administration of study treatmentXx_NEWLINE_xXMajor injuries and/or surgery within the past 4 weeks prior to start of study treatment with incomplete wound healing and/or planned surgery during the on-treatment study periodXx_NEWLINE_xXMajor surgery within 4 weeks of first dose of study drugXx_NEWLINE_xXMajor surgery, other than diagnostic surgery, within 4 weeks prior to day 1, without complete recovery from the surgical procedureXx_NEWLINE_xXMajor surgery or a wound that has not fully healed within 4 weeks of enrollmentXx_NEWLINE_xXMajor surgery within prior 4 weeks and minor surgery within 7 days;Xx_NEWLINE_xXHave had recent major surgery within a minimum of 4 weeks prior to starting study treatment, with the exception of surgical placement for vascular accessXx_NEWLINE_xXPatients who have had major surgery within 4 weeks prior to registration are not eligibleXx_NEWLINE_xXReasonably recovered from preceding major surgery as judged by the Investigator or no major surgery within 4 weeks prior to the start of Day 1 treatmentXx_NEWLINE_xXMajor surgery (as defined by the investigator) within 4 weeks or thoracotomy for pulmonary metastases within 2 weeks prior to first dose of treatment or if still recovering from prior surgery; local surgery of isolated lesions for palliative intent is acceptableXx_NEWLINE_xXSubjects who have had major surgery (such as nephrectomy) or chemotherapy within 2 weeks prior to first dose of drugXx_NEWLINE_xXMajor surgery within 6 weeks prior to study day 1 (subjects must have completely recovered from any previous surgery prior to study day 1); biopsy, diagnostic tonsillectomy, airway tumor debulking or excisional lymph node biopsy do not constitute major surgeryXx_NEWLINE_xXMajor surgery in the last two weeks of starting study therapy; this does not include procedures like biopsy (needle or excisional) or port placement as these are not considered as major surgeryXx_NEWLINE_xXAny major surgery (within 4 weeks of Study Day 1, or has not recovered from the effects of such surgery).Xx_NEWLINE_xXMajor surgery within the four weeks prior to initiating protocol therapyXx_NEWLINE_xXMajor surgery within 4 weeks of first dose of study drugXx_NEWLINE_xXMajor surgery within 4 weeks of drug administrationXx_NEWLINE_xXMajor surgery without full recovery or major surgery within 3 weeks of screeningXx_NEWLINE_xXMajor surgery =< 4 weeks prior to registrationXx_NEWLINE_xXPatients who have undergone major surgery =< 4 weeks prior to starting study drug or who have not recovered from side effects of such therapyXx_NEWLINE_xXPatient who has undergone major surgery =< 4 weeks prior to starting study treatment or who has not recovered from side effects of such procedureXx_NEWLINE_xXMajor surgery within 3 weeks prior to event 1Xx_NEWLINE_xXMajor surgery =< 4 weeks prior to registrationXx_NEWLINE_xXMajor surgery within 4 weeks of study entry, or wound that is not healed from prior surgery or\r\ntraumaXx_NEWLINE_xXPatients who have undergone major surgery =< 3 weeks prior to starting study drug or who have not recovered from side effects of such procedureXx_NEWLINE_xXAny treatment modalities involving major surgery within 4 weeks prior to the start of study treatmentXx_NEWLINE_xXThe patient is not recovered from minor or major surgery and is less than 4 weeks from major surgery prior to starting treatment with pembrolizumabXx_NEWLINE_xXCAPMATINIB EXCLUSION CRITERIA: Major surgery (e.g., intrathoracic, intraabdominal or intrapelvic) within 4 weeks prior (2 weeks for resection of brain metastases) to starting capmatinib; video-assisted thoracic surgery (VATS) and mediastinoscopy will not be counted as major surgery and patients can be enrolled in the study >= 1 week after the procedureXx_NEWLINE_xXAt least 4 weeks from major surgeryXx_NEWLINE_xXMajor surgery within 12 weeks of enrolmentXx_NEWLINE_xXMajor surgery within 4 weeks of starting study treatmentXx_NEWLINE_xXPatients who have had major surgery within 4 weeks prior to study registration or those who have not recovered from complications from a surgery more than 4 weeks prior to registrationXx_NEWLINE_xXMajor surgery (including primary tumour surgery, excluding placement of vascular access) within 4 weeks of the first dose of study drugXx_NEWLINE_xXMajor surgery, radiation therapy or anti-cancer therapy within 2 to 4 weeks of starting study treatment, depending on the patient cohortXx_NEWLINE_xXHas had major surgery within 3 weeks prior to enrollmentXx_NEWLINE_xXHave undergone major surgery =< 4 weeks prior to starting study drug or who have not recovered from side effects of such therapyXx_NEWLINE_xXMajor surgery within 4 weeks of registration is prohibitedXx_NEWLINE_xXSubjects must not have received chemotherapy, or undergone major surgery within 2 weeks and radiotherapy within 24 hours prior to enrollmentXx_NEWLINE_xXMajor surgery or treatment with any other investigational agent within 4 weeksXx_NEWLINE_xXMajor surgery within 4 weeks of initiation of therapy; clearance letter from primary physician requiredXx_NEWLINE_xXMajor surgery within 4 weeks prior to first study doseXx_NEWLINE_xXMajor surgery within 4 weeks before starting study treatment or scheduled for surgery during the projected course of the studyXx_NEWLINE_xXMajor surgery in the past 4 weeks.Xx_NEWLINE_xXHad major surgery within 4 weeks prior to study drug treatment.Xx_NEWLINE_xXMajor surgery (within 4 weeks prior to the start of cycle 1), except for procedures that are performed for diagnostic purposesXx_NEWLINE_xXMajor injuries and/or surgery with then past 4 weeks prior to the start of study treatment with incomplete wound healing and/or planned surgery during the on-treatment study periodXx_NEWLINE_xXSubjects who have received radiation therapy, major surgery, other locoregional therapy, within 4 weeks prior to the first dose of study drugXx_NEWLINE_xXA history of any major surgery within 6 weeks prior to dosingXx_NEWLINE_xXAt least 2 weeks must have elapsed from any prior surgeryXx_NEWLINE_xXAny major surgery within the last 3 weeksXx_NEWLINE_xXMajor surgery within four weeks before day 1Xx_NEWLINE_xXMajor surgery or a wound that has not fully healed within 4 weeks of initiation of therapyXx_NEWLINE_xXAt least 2 weeks must have elapsed from any prior surgeryXx_NEWLINE_xXSurgery within 3 weeks prior to enrollmentXx_NEWLINE_xXPatients who have had major surgery within 4 weeks of initiation of study medicationXx_NEWLINE_xXMajor surgery in the past 16 weeksXx_NEWLINE_xXMajor surgery or radiation therapy within 4 weeks prior to the Baseline Visit.Xx_NEWLINE_xXPatients who have undergone major surgery =< 2 weeks prior to starting study drug or who have not recovered from side effects of such therapyXx_NEWLINE_xXMajor surgery within two weeks prior to trial entryXx_NEWLINE_xXMajor surgery within 4 weeks prior to registrationXx_NEWLINE_xX> 4 weeks since major surgeryXx_NEWLINE_xXPatients had a major surgery within 3 weeks prior to study entry or who have not recovered from side effects of such procedureXx_NEWLINE_xX>= 2 weeks since major surgeryXx_NEWLINE_xXMajor surgery, other than diagnostic surgery, within 2 weeksXx_NEWLINE_xXMajor surgery within 3 weeks of the start of study treatment, without complete recoveryXx_NEWLINE_xXNewly diagnosed MCL: Major surgery within 4 weeks or vaccination with live attenuated vaccines within 4 weeks of the first dose of study drugXx_NEWLINE_xXMajor surgery, or not recovered from major surgery within 4 weeks before the first dose of study treatmentXx_NEWLINE_xXPatients who have undergone major surgery < 4 weeks of initiation of study medication or who have not recovered from side effects of such procedureXx_NEWLINE_xXMajor surgery within 2 weeks of the start of study treatment, or ongoing complications from surgeries performed previouslyXx_NEWLINE_xXSurgery intent within 4 weeksXx_NEWLINE_xXAny of the following prior therapies:\r\n* Radiation to >= 25% of bone marrow\r\n* Major surgery (i.e., laparotomy), open biopsy, or significant traumatic injury =< 4 weeks prior to registration; minor surgery =< 2 weeks prior to registration; insertion of a vascular access device is not considered major or minor surgery in this regardXx_NEWLINE_xXPatients with major surgery or radiation therapy within 4 weeks prior to first study dose.Xx_NEWLINE_xXMajor surgery within 4 weeks prior to day 1Xx_NEWLINE_xXMajor surgery, other than diagnostic surgery, within 4 weeks prior to Day 1, without complete recoveryXx_NEWLINE_xXPatients who have had major surgery within 6 weeks of enrollment in the studyXx_NEWLINE_xXPatients must have fully recovered from all effects of surgery; patients must have had at least two weeks after minor surgery and four weeks after major surgery before starting therapy; minor procedures requiring “Twilight” sedation such as endoscopies or mediport placement may only require a 24 hour waiting period, but this must be discussed with an investigatorXx_NEWLINE_xXA minimum of 4 weeks from any major surgery prior to start of study drugXx_NEWLINE_xXPlanned major surgeryXx_NEWLINE_xXMajor surgery within 4 weeks prior to Randomization VisitXx_NEWLINE_xXMajor surgery, other than diagnostic surgery, within 4 weeks prior to first dose, without complete recovery.Xx_NEWLINE_xXMajor surgery within 4 weeks of first dose of study drugXx_NEWLINE_xXPatients, who have had a major surgery or significant traumatic injury within 4 weeks of start of study drug, patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia) or patients that may require major surgery during the course of the studyXx_NEWLINE_xXHave major surgery, other than diagnostic surgery, within 4-weeks prior to Day 1Xx_NEWLINE_xXPrior systemic chemotherapy, major surgery, or thoracic radiation within 3 weeks of study initiation.Xx_NEWLINE_xXMajor surgery <=4 weeks before the first dose of study treatment. Subjects must have also fully recovered from any surgery (major or minor) and/or its complications before initiating study treatment.Xx_NEWLINE_xXHas undergone major surgery within 3 weeks of Study Day 1, Subject must have recovered adequately from any toxicity and/or complications from the intervention prior to starting therapy;Xx_NEWLINE_xXFailure to recover from major surgery or traumatic injury within 4 weeks or minor surgery within 2 weeks prior to Day 1 of treatment.Xx_NEWLINE_xXMajor surgery within 4 weeks prior to study treatment.Xx_NEWLINE_xXMajor surgery in last 4 weeks, minor surgery in the last 2 weeksXx_NEWLINE_xXMajor surgery within 4 weeks prior to starting INC280Xx_NEWLINE_xXMajor surgery (eg., requiring general anesthesia) within 3 weeks before screening, or will not have fully recovered from surgery, or has surgery planned during the time the subject is expected to participate in the studyXx_NEWLINE_xXPatients who have undergone major surgery <4 weeks prior to starting study drug.Xx_NEWLINE_xXHave had major surgery ? 2 weeks prior to starting treatment with Andes-1537 or who have not recovered from side effects of such surgeryXx_NEWLINE_xXMajor surgery/surgical therapy for any cause within 4 weeks of Screening;Xx_NEWLINE_xXMajor surgery within four weeks before cycle 1 day 1Xx_NEWLINE_xXPatient had major surgery within 4 weeks prior to the first dose.Xx_NEWLINE_xXAt least 4 weeks beyond treatment (chemotherapy, immunotherapy and/or radiation therapy) or major surgery and recovered from all acute toxicities.Xx_NEWLINE_xXMajor surgery within 4 weeks prior to first dose of STA-9090Xx_NEWLINE_xXPatients who have undergone major surgery =< 2 weeks prior to starting study drug or who have not recovered from side effects of such therapyXx_NEWLINE_xXsurgery was completed ?4 weeks prior to baselineXx_NEWLINE_xXMajor surgery within 4 weeks or minor surgery within 2 weeks of the start of study drug.Xx_NEWLINE_xXMajor surgery, other than diagnostic surgery, within 4 weeks prior to the first dose of test drug.Xx_NEWLINE_xXMajor surgery within 4 weeks prior to study entryXx_NEWLINE_xXMajor surgery or invasive intervention within 4 weeks prior to first doseXx_NEWLINE_xXAny major surgery within the last four weeks.Xx_NEWLINE_xXMajor surgery within 4 weeks prior to study enrollment.Xx_NEWLINE_xXHas received major surgery within the 4 weeks prior to starting the trial.Xx_NEWLINE_xXMajor surgery within 2 weeks of starting study treatment and patients must have recovered from any effects of any major surgery.Xx_NEWLINE_xXAny major surgery within the last four weeks.Xx_NEWLINE_xXMajor surgery within 2 weeks of starting study treatment and patients must have recovered from any effects of any major surgeryXx_NEWLINE_xXMajor surgery within the last 4 weeks; minor surgery within the last 2 weeksXx_NEWLINE_xXMajor surgery within 4 weeks prior to inclusionXx_NEWLINE_xXPatients who have undergone major surgery =< 3 weeks prior to starting study drug or who have not recovered from side effects of such procedureXx_NEWLINE_xXAt least 4 weeks beyond treatment (chemotherapy, immunotherapy and/or radiation therapy) or major surgery and recovered from all acute toxicitiesXx_NEWLINE_xXMajor surgery or radiation ? 2 weeks prior to starting study treatment or who have not recovered from side effects of surgery or radiationXx_NEWLINE_xXAt least 4 weeks must have elapsed from major surgery or radiation therapy prior to randomizationXx_NEWLINE_xXAt least 4 weeks have elapsed since the completion of major surgery, and the patient has fully recovered from this surgery and any post-surgical complicationsXx_NEWLINE_xXMajor surgery within 4 weeks of first dose of study drugXx_NEWLINE_xXPatients must be at least 2 weeks from major surgery, radiation therapy, participation in other investigational trials and must have recovered from clinically significant toxicities of these prior treatmentsXx_NEWLINE_xXMajor surgery within 2 weeks of starting study treatment and patients must have recovered from any effects of any major surgery.Xx_NEWLINE_xXMajor surgery or wound that has not fully healed within 4 weeks or vaccination with live attenuated vaccines within 4 weeks of the first dose of study drugs.Xx_NEWLINE_xXSubjects who have had major surgery within 2 weeks prior to first dose of drugXx_NEWLINE_xXAt least 4 weeks must have elapsed since the last chemotherapy, radiotherapy or major surgeryXx_NEWLINE_xXChemotherapy or surgery within 4 weeks prior to treatment startXx_NEWLINE_xXPatient who has undergone major surgery =< 4 weeks prior to starting study treatment or who has not recovered from side effects of such procedure; note: core needle biopsy, diagnostic tonsillectomy or excisional lymph node biopsy do not constitute major surgeryXx_NEWLINE_xXChemotherapy or surgery within 4 weeks prior to treatment startXx_NEWLINE_xXMajor surgery within 4 weeks prior to day 1 of the study or who have not recovered from prior surgeryXx_NEWLINE_xXPrior major surgery =< 3 weeks before study drug or not recovered from side effects of such procedureXx_NEWLINE_xXMajor surgery within four weeks before first IMP administration.Xx_NEWLINE_xXParticipants who have undergone major systemic surgery =< 2 weeks prior to starting study drug or who have not recovered from side effects of such therapyXx_NEWLINE_xXReceived major surgery =< 2 weeks prior to registration, subject must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXMajor surgery within 4 weeks of registrationXx_NEWLINE_xXPlanned major surgery during the studyXx_NEWLINE_xXMajor surgery within 4 weeks before randomizationXx_NEWLINE_xXPlanned major surgery during the study or within 4 weeks of Cycle 1, Day 1Xx_NEWLINE_xXPatients must be at least 4 weeks from radiation therapy or major surgery and have recovered from prior toxicitiesXx_NEWLINE_xXMajor surgery within 8 weeks of study enrollment or planned major surgery during study and up to 6 months after discontinuation of study drugXx_NEWLINE_xXMajor surgery =< 3 weeks prior to registration or failure to adequately recover from surgeryXx_NEWLINE_xXMajor surgery within prior 4 weeks (the surgical incision should be fully healed prior to drug administration)Xx_NEWLINE_xXMajor surgery within 2 weeks before day 1Xx_NEWLINE_xXPatients who are less than 4 weeks post-operative (op) after major surgeryXx_NEWLINE_xXNo planned major surgeryXx_NEWLINE_xXPlanned major surgeryXx_NEWLINE_xXMajor surgery without full recovery or major surgery within 3 weeks of Screening.Xx_NEWLINE_xXMajor surgery =< 4 weeks prior to registration or have not recovered from side effects of such therapyXx_NEWLINE_xXMajor surgery within 4 weeks of first dose of study drugXx_NEWLINE_xXMinimum of four weeks since any major surgery, completion of radiationXx_NEWLINE_xXPatients who have undergone major surgery within 4 weeks prior to study enrollmentXx_NEWLINE_xXPatients less than 4 weeks post major surgeryXx_NEWLINE_xXSubjects who have had a major surgery or significant trauma within 4 weeks before the start of study treatmentXx_NEWLINE_xXMajor surgery within 2 weeks of first dose of study drug; patients must have recovered from the effects of any surgery performed greater than 2 weeks previouslyXx_NEWLINE_xXMajor surgery within 2 weeks of first dose of study drug; patients must have recovered from the effects of any surgery performed greater than 2 weeks priorXx_NEWLINE_xXMajor surgery within four weeks before day 1Xx_NEWLINE_xXMajor surgery within 6 weeks prior to study day 1 (subjects must have completely recovered from any previous surgery prior to study day 1)Xx_NEWLINE_xXPatients who have undergone major surgery =< 4 weeks prior to starting study treatment or who have not recovered from side effects of such procedureXx_NEWLINE_xXPatients who have undergone major surgery within 4 weeks prior to starting the study treatmentXx_NEWLINE_xXPatients who have undergone major surgery =< 4 weeks prior to starting study drug or who have not recovered from side effects of such therapyXx_NEWLINE_xXAt least 2 weeks since prior radiotherapy or stereotactic radiosurgery, and 4 weeks since prior major surgery at time of study enrollmentXx_NEWLINE_xXPatients, who have had a major surgery or significant traumatic injury within 4 weeks of start of study drug, patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia) or patients that may require major surgery during the course of the studyXx_NEWLINE_xXMajor surgery within 2 weeks of starting study treatment and patients must have recovered from any effects of any major surgeryXx_NEWLINE_xXPatients who have undergone major surgery =< 2 weeks prior to starting study drug or who have not recovered from side effects of such therapyXx_NEWLINE_xXPatients who have had major surgery without full recovery or major surgery within three weeks of the start of vaccine treatmentXx_NEWLINE_xXPatients who have had a major surgery or significant traumatic injury within 4 weeks of start of study drug, patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia) or patients that may require major surgery during the course of the studyXx_NEWLINE_xXMajor surgery, other than diagnostic surgery, occurring 4 weeks prior to study entry; splenectomy will not be considered an exclusionary major surgeryXx_NEWLINE_xXMajor surgery within 4 weeks prior to the screening visitXx_NEWLINE_xXSubject has had major surgery within 4 weeks prior to the first study dose.Xx_NEWLINE_xXHas had major surgery within 2 weeks prior to enrollmentXx_NEWLINE_xXMajor surgery within 4 weeks prior to screening.Xx_NEWLINE_xXMajor surgery within 4 weeks prior to randomizationXx_NEWLINE_xXParticipants with major surgery in the 4 weeks prior to randomization (Video-assisted thoracoscopic surgery (VATS) and/or mediastinoscopy is not considered major surgery).Xx_NEWLINE_xXHas had major surgery to liver or other site within 4 weeks prior to the first dose of study drug.Xx_NEWLINE_xXMajor surgery within 4 weeks prior to first dose of study drug.Xx_NEWLINE_xXMajor surgery within 4 weeks prior to study day 1 (patients must have recovered completely from any previous surgery prior to study day 1).Xx_NEWLINE_xXMajor surgery for any reason, except diagnostic biopsy, within 4 weeks of enrolment and/or if the subject has not fully recovered from the surgery within 4 weeks of enrolmentXx_NEWLINE_xXPatients who have undergone major surgery =< 4 weeks prior to starting study treatment, who have not recovered from side effects of such procedureXx_NEWLINE_xXMajor surgery within 4 weeks before first dose of study drug.Xx_NEWLINE_xXMajor surgery within 4 weeks before first dose of study drug.Xx_NEWLINE_xXSubject has had major surgery, other than diagnostic surgery, within 4 weeks prior to treatment in study.Xx_NEWLINE_xXmajor surgery within 4 weeks of first dose of study drugXx_NEWLINE_xXMajor surgery within 4 weeks before randomization;Xx_NEWLINE_xXMajor surgery </= 4 weeks before study treatmentXx_NEWLINE_xXMajor surgery or radiation therapy < 4 weeks of starting study treatmentXx_NEWLINE_xXMajor surgery within 2 weeks prior to registration; patients must have recovered from any effects of any major surgeryXx_NEWLINE_xXMajor surgery (excluding placement of vascular access) within 4 weeks of the first dose of study treatment.Xx_NEWLINE_xXTime elapsed from previous therapy must be ? 3 weeks for systemic therapy, ? 2 weeks for radiation therapy or major surgery.Xx_NEWLINE_xXMajor surgery within 2 weeks prior to randomization.Xx_NEWLINE_xXMajor surgery or trauma within four weeks before enrollment.Xx_NEWLINE_xXMajor surgery within 4 weeks prior to first doseXx_NEWLINE_xXMajor surgery within 2 weeks prior to the first dose of lenvatinib.Xx_NEWLINE_xXMajor surgery less than 1 month before start of the studyXx_NEWLINE_xXMajor surgery <4 weeks or radiation therapy <2 weeks of patient registration.Xx_NEWLINE_xXHave had any major surgery within four weeks of enrollment.Xx_NEWLINE_xXHas had major surgery within 3 weeks prior to enrollment NOTE: Minor surgery (e.g., minor biopsy, central venous catheter placement) is permitted within 3 weeks prior to enrollment.Xx_NEWLINE_xXHas had major surgery within 4 weeks, received radiation therapy within 2 weeks prior to randomization, or has not recovered (i.e., ? Grade 1 or at baseline) from AEs due to prior treatment.Xx_NEWLINE_xXSubject had a major surgery within 4 weeks prior to day 1.Xx_NEWLINE_xXMajor surgery within 4 weeks before starting study treatment or scheduled for surgery during the projected course of the studyXx_NEWLINE_xXMajor injuries or surgery within the 4 weeks prior to initiation of therapy with incomplete wound healing or planned surgery during the on-study treatment periodXx_NEWLINE_xXMajor surgery within 4 weeks prior to enrollmentXx_NEWLINE_xXMajor surgery for any reason, except diagnostic biopsy, within 4 weeks and/or if the subject has not fully recovered from the surgery within 4 weeksXx_NEWLINE_xXMajor surgery within 4 weeks of randomization;Xx_NEWLINE_xXMajor surgery requiring the use of general anesthetic within 4 weeks of study enrollmentXx_NEWLINE_xXMajor surgery within 4 weeks of the first dose of study drugXx_NEWLINE_xXPatients that have undergone major surgery within the last 4 weeks before enrollment;Xx_NEWLINE_xXSurgery within 4 weeks prior to first doseXx_NEWLINE_xXMajor surgery less than 1 month before the start of the studyXx_NEWLINE_xXSubjects having undergone a major surgery within the last 6 weeksXx_NEWLINE_xXAre at least 4 weeks from major surgery and recovered.Xx_NEWLINE_xXMajor surgery, other than diagnostic surgery (e.g., surgery done to obtain a biopsy for diagnosis without removal of an organ), within 4 weeks prior to first dose.Xx_NEWLINE_xXMajor surgery within 4 weeks prior to Day 1 studyXx_NEWLINE_xXMajor surgery within 4 weeks of first dose of study drugXx_NEWLINE_xXSystemic cytotoxic chemotherapy, antineoplastic biologic therapy, or major surgery within 3 weeks of the first dose of study medicationXx_NEWLINE_xXMajor surgery without full recovery or major surgery within 3 weeks of Screening.Xx_NEWLINE_xXPatients who have had major surgery within 4 weeks of initiation of study medication, excluding the placement of vascular accessXx_NEWLINE_xXMajor surgery ? 2 weeks prior to starting study drug or still recovering from post operative side effects.Xx_NEWLINE_xXMajor surgery within the previous 4 weeksXx_NEWLINE_xXHave received prior chemotherapy, other investigational therapy, or major surgery within 4 weeks of Day 1;Xx_NEWLINE_xXSevere infection or major surgery within 4 weeks, or oral or IV antibiotics treatment within 2 weeks prior to enrollmentXx_NEWLINE_xXHad a major surgery or significant trauma within 4 weeks before the start of anetumab ravtansineXx_NEWLINE_xXMajor surgery within 4 weeks before the first dose of study drug.Xx_NEWLINE_xXMajor surgery within 4 weeks of enrollmentXx_NEWLINE_xXMajor surgery within 4 weeks of starting trialXx_NEWLINE_xXSurgery within 4 weeks of study drug administrationXx_NEWLINE_xXMajor surgery within 4 weeks of first dose of study drug.Xx_NEWLINE_xXMajor surgeryXx_NEWLINE_xXMajor surgery within 4 weeks of study treatmentXx_NEWLINE_xXMajor surgery within 4 weeks of first dose of study drugXx_NEWLINE_xXMajor surgery =< 2 weeks prior to starting a study drug or who have not recovered from side effects of such therapyXx_NEWLINE_xXHave undergone major surgery or received any investigational therapy in the 4 weeks prior to study entry.Xx_NEWLINE_xXMajor surgery within 4 weeksXx_NEWLINE_xXPatients with major surgery within 3 weeks prior to study entry or who have not recovered from side effects of such procedureXx_NEWLINE_xXReceived major surgery, radiotherapy, or immunotherapy within 4 weeks of GSK2879552 administration.Xx_NEWLINE_xXPatients who:\r\n* Have had a major surgery or significant traumatic injury within 4 weeks from day 1 of study drug\r\n* Have not recovered from the side effects of any major surgery (defined as requiring general anesthesia) or\r\n* Are anticipated to require major surgery during the course of the studyXx_NEWLINE_xXRecent major surgeryXx_NEWLINE_xXAny major surgery within 4 weeks or a diagnostic procedure (e.g. incision, needle biopsy) within 1 day of study drug administrationXx_NEWLINE_xXMajor surgery or any anti-cancer therapy within 2 weeks of randomizationXx_NEWLINE_xXMajor surgery within 3 weeks prior to randomization or scheduled for surgery during the studyXx_NEWLINE_xXMajor surgery =< 4 weeks prior to registration; minor surgery =< 2 weeks prior to registration; insertion of a vascular access device is not considered major or minor surgery; subjects must have recovered from all surgery related toxicities to =< grade 1 or to baseline if subject started with > grade 1 toxicity, not otherwise violating the above inclusion criteriaXx_NEWLINE_xXMajor surgery within 4 weeks prior to Day 1 of study or who have not recovered from prior surgeryXx_NEWLINE_xXPatients must be at least 4 weeks from major surgery and must be fully recoveredXx_NEWLINE_xXHave had a major surgery or significant trauma within 4 weeks of enrollment (Part 1) or randomization (Part 2).Xx_NEWLINE_xXMajor surgery within 4 weeks of study treatmentXx_NEWLINE_xXHave a planned major surgery.Xx_NEWLINE_xXMajor surgery within 2 weeks of the first dose of study treatmentXx_NEWLINE_xXSubject has had major surgery within 4 weeks prior to the first study dose.Xx_NEWLINE_xXMajor surgery ? 2 weeks and recovered from any clinically significant effects of recent surgery.Xx_NEWLINE_xXTrauma or major surgery within 4 weeks of first study drug administrationXx_NEWLINE_xXMajor surgery, excluding laparoscopy, within 4 weeks of the start of study treatment, without complete recoveryXx_NEWLINE_xXPatients had a major surgery within 3 weeks prior to study entry or who have not recovered from side effects of such procedureXx_NEWLINE_xXMajor surgery, other than diagnostic surgery, within 2 weeksXx_NEWLINE_xXPatients who have undergone major surgery =< 4 weeks prior to registration or have not recovered from side effects of such procedure are not eligible for participationXx_NEWLINE_xXMajor surgery within 4 weeks of enrollmentXx_NEWLINE_xXMajor surgery within 4 weeks of starting treatment.Xx_NEWLINE_xXMajor injuries and/or surgery within the past 4 weeks prior to start of study treatment with incomplete wound healing and/or planned surgery during the on-treatment study periodXx_NEWLINE_xXPatient has had major surgery or a wound that has not fully healed within 4 weeks of starting study drugsXx_NEWLINE_xXMajor surgery within 4 weeks of the start of study treatment, without complete recoveryXx_NEWLINE_xXMajor surgery within 4 weeks prior to enrollment (day 1 visit)Xx_NEWLINE_xXMajor surgery =< 4 weeks prior to registration of the study or who have not recovered from prior surgery regardless of time since surgeryXx_NEWLINE_xXPatients must not have disease that is currently amenable to surgery; prior surgery is allowed no less than 6 weeks prior to study entryXx_NEWLINE_xXMajor surgery within 4 weeks of first dose of study drugXx_NEWLINE_xXMajor surgery within 4 weeks of starting the study treatmentXx_NEWLINE_xXMajor surgery within 4 weeks of the start of study treatment defined as those surgeries that require general anesthesia; insertion of a vascular access device is NOT considered major surgeryXx_NEWLINE_xXMajor surgery within 2 weeks of study drug administrationXx_NEWLINE_xXMajor surgery (within 4 weeks prior to the start of cycle 1), other than for diagnosisXx_NEWLINE_xXAny major surgery within the last 3 weeksXx_NEWLINE_xXMajor surgery within 2 weeks of first dose of study drug; patients must have recovered from the effects of any surgery performed greater than 2 weeks previouslyXx_NEWLINE_xXLast surgery > 10 weeks from enrollmentXx_NEWLINE_xXSurgery less than two weeks before enrollmentXx_NEWLINE_xXMajor surgery within 4 weeks of initiation of therapyXx_NEWLINE_xXParticipants who have undergone major surgery =< 4 weeks prior to starting study drug or who have not recovered from side effects of the surgeryXx_NEWLINE_xXMajor surgery =< 4 weeks prior to starting study regimen or who have not recovered from surgeryXx_NEWLINE_xXHad major surgery within 4 weeks of first dose of study drugXx_NEWLINE_xXSubjects who had major surgery within 4 weeks of the first day of study drug.Xx_NEWLINE_xXPatient underwent major systemic surgery =< 2 weeks prior to starting the trial treatment or who has not recovered from the side effects of such surgeryXx_NEWLINE_xXMajor surgery within 4 weeks of the first dose of study drug.Xx_NEWLINE_xXAny major surgery or open biopsy completed >= 4 weeks prior to randomizationXx_NEWLINE_xXMajor surgery within 4 weeks prior to first study drug administrationXx_NEWLINE_xXPatient who has undergone major surgery =< 4 weeks prior to starting study treatment or who has not recovered from side effects of such procedureXx_NEWLINE_xXMajor surgery within 6 weeks prior to study day 1 (subjects must have completely recovered from any previous surgery prior to study day 1)Xx_NEWLINE_xXMajor surgery within 4 weeks of initiation of therapyXx_NEWLINE_xXMajor surgery (within 4 weeks prior to the start of cycle 1), except for procedures that are performed for diagnostic purposesXx_NEWLINE_xXPatients must not have received chemotherapy, radiation therapy, or undergone major surgery within 4 weeks prior to enrollmentXx_NEWLINE_xXPatients who have undergone major surgery =< 2 weeks prior to starting study drug or who have not recovered from side effects of such therapyXx_NEWLINE_xXMajor surgery within four weeks before day -7Xx_NEWLINE_xXMajor surgery within three weeks before cycle 1 day 1Xx_NEWLINE_xXSubjects that have undergone major surgery within 4 weeks prior to the first dose of study drug are not eligibleXx_NEWLINE_xXAt least 4 weeks since major unrelated surgery, with full recoveryXx_NEWLINE_xXMajor surgery within four weeks before initiation of therapyXx_NEWLINE_xXAt least 4 weeks must have elapsed from major surgery prior to starting study drugXx_NEWLINE_xXNo major surgery within 2 weeks of starting study treatmentXx_NEWLINE_xXSurgery: at least 2 weeks since undergoing any major surgery and must be recovered from effects of surgeryXx_NEWLINE_xXMajor surgery within 2 weeks before day 1Xx_NEWLINE_xXAt least 4 weeks must have elapsed from major surgeryXx_NEWLINE_xXPatients who have undergone major surgery =< 2 weeks prior to registration to study or who have not recovered from the side-effects of surgeryXx_NEWLINE_xXPrior major surgery less than 4 weeks prior to the start of the study;Xx_NEWLINE_xXNo major surgery within 4 weeks prior to study entryXx_NEWLINE_xXPatients who have undergone major surgery within 2 weeks prior to study enrollment or who have not recovered from a major surgeryXx_NEWLINE_xXPatients who have undergone major surgery =< 4 weeks prior to registration or who have not recovered from side effects of such procedure are not eligible for participationXx_NEWLINE_xXMajor surgery within 4 weeks before first dose of study drug.Xx_NEWLINE_xXMajor surgery within 4 weeks of registrationXx_NEWLINE_xXMajor surgery or radiation therapy within 4 weeks of cycle 1, day 1Xx_NEWLINE_xXMajor surgery within 4 weeks prior to first dose.Xx_NEWLINE_xXCOHORT A: Major surgery within 4 weeks of enrollment (week 1 visit)Xx_NEWLINE_xXCOHORT B: Major surgery within 4 weeks of enrollment (week 1 visit)Xx_NEWLINE_xXMajor surgery or invasive intervention within 4 weeks prior to randomizationXx_NEWLINE_xXMajor surgery, chemotherapy, hormonal or immunologic therapy =< 3 weeks prior to registrationXx_NEWLINE_xXMajor surgery within 2 weeks of starting study treatment and patients must have recovered from any effects of any major surgery.Xx_NEWLINE_xXParticipants who have undergone major surgery =< 4 weeks prior to starting study drug or who have not recovered from side effects of the surgeryXx_NEWLINE_xXAny major surgery within the last 4 weeksXx_NEWLINE_xXMajor surgery, radiation therapy, or systemic anti-cancer therapy within 4 weeks of study treatment start (6 weeks for mitomycin C or nitrosoureas)Xx_NEWLINE_xXSubject has had major surgery within 4 weeks prior to the first study dose.Xx_NEWLINE_xXSubjects who have had major surgery within 4 weeks prior to entering the studyXx_NEWLINE_xXMajor surgery within 3 weeks prior to first doseXx_NEWLINE_xXMajor surgery within 2 weeks of study treatment initiation and patients must have recovered from any effects of any major surgery.Xx_NEWLINE_xXMajor surgery within 2 weeks of first dose of lenvatinibXx_NEWLINE_xXMajor surgery within 4 weeks prior to study enrollment.Xx_NEWLINE_xXPatients who have had a major surgery or significant traumatic injury within 4 weeks of start of study drug, patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia) or patients that may require major surgery during the course of the studyXx_NEWLINE_xXMajor surgery within 3 weeks prior to first doseXx_NEWLINE_xXPatients who are within 4 weeks of major surgery or within 2 weeks of minor surgeryXx_NEWLINE_xXNo major surgery within 4 weeks prior to enrollmentXx_NEWLINE_xXAt least 4 weeks must have elapsed from major surgery or radiation therapy prior to randomizationXx_NEWLINE_xXMajor surgery or radiation therapy within 4 weeks of enrollmentXx_NEWLINE_xXA minimum of 4 weeks from any major surgery prior to start of study drugXx_NEWLINE_xXPatients must be > 4 weeks from any major surgeryXx_NEWLINE_xXMajor surgery within 4 weeks or minor surgery within 7 days of the first day of study drug dosingXx_NEWLINE_xXMajor surgery within 3 weeks prior to first doseXx_NEWLINE_xXMajor surgery within 3 weeks before the first dose of study drug.Xx_NEWLINE_xXMajor surgery < 4 weeks or minor surgery (e.g. talc pleurodesis, excisional biopsy, etc) < 2 weeks prior to the first day of study defined treatmentXx_NEWLINE_xXMajor surgery within 4 weeks prior to enrollment (day 1 visit)Xx_NEWLINE_xXPatients who have undergone major surgery =< 4 weeks prior to starting study treatment, who have not recovered from side effects of such procedureXx_NEWLINE_xXMajor surgery within 4 weeks of random assignmentXx_NEWLINE_xXParticipants who have undergone any major surgery =< 2 weeks prior to starting study drug or who have not recovered from side effects of such therapyXx_NEWLINE_xXPatients must be at least 2 weeks from major surgery, radiation therapy, participation in other investigational trials and must have recovered from clinically significant toxicities of these prior treatmentsXx_NEWLINE_xXAt least 2 weeks must have elapsed from any prior surgeryXx_NEWLINE_xXMajor surgery within 4 weeks prior to entering the studyXx_NEWLINE_xXMajor surgery, excluding laparoscopy, within 4 weeks of the start of study treatment, without complete recoveryXx_NEWLINE_xXPatients who have undergone major surgery =< 2 weeks prior to starting study drug or who have not recovered from side effects of such therapyXx_NEWLINE_xXMajor surgery within 3 weeks prior to first doseXx_NEWLINE_xXMajor surgery =< 4 weeks prior to registration of the study or who have not recovered from prior surgeryXx_NEWLINE_xXPatients, who have had a major surgery or significant traumatic injury within 4 weeks of start of study drug, patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia) or patients that may require major surgery during the course of the studyXx_NEWLINE_xXRecovery from any major or minor surgeries; patient must be 4 weeks post-major surgery and 2 weeks post-minor surgeryXx_NEWLINE_xXMajor surgery within the last 4 weeks; minor surgery within the last 2 weeksXx_NEWLINE_xXMajor surgery < 4 weeks from the start of treatmentXx_NEWLINE_xXParticipants who have undergone any major surgery =< 2 weeks prior to starting study drug or who have not recovered from side effects of such therapyXx_NEWLINE_xXSurgery within 4 weeks prior to first doseXx_NEWLINE_xXMajor surgery within 4 weeks prior to first doseXx_NEWLINE_xXSurgery within 4 weeks prior to first dose.Xx_NEWLINE_xXPatients who have undergone major surgery or radiotherapy ? 3 weeks prior to starting study drug or who have not recovered from side effects of such procedure;Xx_NEWLINE_xXMajor surgery or radiation therapy within four weeks of the first dose of ARQ 087Xx_NEWLINE_xXTherapy must begin =< 5 weeks after surgeryXx_NEWLINE_xXMajor surgery within 4 weeks before first day of study drug dosingXx_NEWLINE_xXMajor surgery within 4 weeks prior to entering the studyXx_NEWLINE_xXMajor surgery within 4 weeks of registration is prohibitedXx_NEWLINE_xXAny major surgery or radiation therapy within four weeks.Xx_NEWLINE_xXPatients who have undergone major surgery =< 4 weeks prior to starting study drug or who have not recovered from side effects of such therapyXx_NEWLINE_xXMajor surgery or radiation therapy within 4 weeks of enrollment (day 1 visit)Xx_NEWLINE_xXMajor surgery or radiation therapy within 4 weeks before first study drug administration.Xx_NEWLINE_xXSurgery within 2 weeks prior to dosingXx_NEWLINE_xXPatients who have not recovered from the side effects of any major surgeryXx_NEWLINE_xXPatients with major surgery less than 3 months prior to start study drug or who have still side effects of such therapy.Xx_NEWLINE_xXMajor surgery within 4 weeksXx_NEWLINE_xXMajor surgery within 4 weeks of Study Day 1Xx_NEWLINE_xXPatients must not have received chemotherapy, radiation therapy, or undergone major surgery within 4 weeks prior to enrollmentXx_NEWLINE_xXMajor surgery within 3 weeks prior to day 1 of study treatment from which the patient has not completely recoveredXx_NEWLINE_xXMajor surgery, excluding laparoscopy, within 4 weeks of the start of study treatment, without complete recoveryXx_NEWLINE_xXMajor surgery or radiation therapy < 4 weeks of starting study treatmentXx_NEWLINE_xXPatients who have received any cytotoxic therapy, immunotherapy, antitumor vaccines, monoclonal antibodies or major surgery in the 4 weeks prior to the start of the studyXx_NEWLINE_xXPatients, who have had a major surgery or significant traumatic injury within 4 weeks of start of study drug, patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia) or patients that may require major surgery during the course of the studyXx_NEWLINE_xX>= 2 weeks since major surgeryXx_NEWLINE_xXMajor surgery, other than diagnostic surgery, within 2 weeksXx_NEWLINE_xXMajor surgery, excluding laparoscopy, within 4 weeks of the start of study treatment, without complete recoveryXx_NEWLINE_xXPatient has had major surgery within the last 3 weeksXx_NEWLINE_xXMajor surgery within 4 weeks of study randomisation.Xx_NEWLINE_xXNo major surgery or radiation in the prior 4 weeks prior to enrollmentXx_NEWLINE_xXPatients who have undergone major surgery =< 4 weeks prior to starting study drug or who have not recovered from side effects of such therapyXx_NEWLINE_xXPatient has undergone a major surgery, other than diagnostic surgery (i.e. surgery done to obtain a biopsy for diagnosis without removal of an organ) within four weeks prior to day 1 of treatment on this studyXx_NEWLINE_xXPatients having undergone major surgery less than 4 weeks prior to enrollment or have not fully recovered from prior surgeryXx_NEWLINE_xXMajor surgery within 4 weeks prior to day 1 of the study or who have not recovered from prior surgeryXx_NEWLINE_xXRecent major surgery (within 4 weeks prior to start of Cycle 1), other than for diagnosisXx_NEWLINE_xXPatients who have had a major surgery or significant traumatic injury within 4 weeks of start of study drug, patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia), or patients that may require major surgery during the course of the studyXx_NEWLINE_xXHave undergone major surgery =< 2 weeks prior to starting BKM120 or BYL719 or have not recovered from side effects of such therapyXx_NEWLINE_xXMinimum of four weeks since any major surgery or since completion of radiation (patients should have adequately recovered from the acute toxicities of any prior therapy)Xx_NEWLINE_xXMajor surgery =< 4 weeks prior to registration or have not recovered from side effects of such therapyXx_NEWLINE_xXHas had major surgery within 3 weeks prior to receiving the first dose of study treatment or has not recovered adequately from toxicity and/or complications from an intervention prior to receiving the first dose of study treatment.Xx_NEWLINE_xXAt least 4 weeks must have elapsed from major surgeryXx_NEWLINE_xXMajor surgery within 2 weeks of starting study treatment, and subjects must have recovered from any effects of any major surgery;Xx_NEWLINE_xXMajor surgery planned within 4 weeks of the first dose of study drugXx_NEWLINE_xXMajor surgery within 3 weeks prior to first doseXx_NEWLINE_xXMajor surgery within 3 weeks prior to first study drug administration.Xx_NEWLINE_xXAny major surgery within 4 weeks of starting treatment on protocolXx_NEWLINE_xXRecent major surgery (within 4 weeks), other than for diagnosisXx_NEWLINE_xXRandomization within 12 weeks of surgeryXx_NEWLINE_xXMajor surgery within 4 weeks before randomizationXx_NEWLINE_xXMajor surgery within 4 weeks (or within 2 weeks following consultation with and approval of Medical Monitor)Xx_NEWLINE_xXPatients who have had major surgery must be fully recovered and >= 4 weeks post-operative prior to enrolling on studyXx_NEWLINE_xXMajor surgery within 4 weeks of screeningXx_NEWLINE_xXMajor surgery within 4 weeks before the start of study therapy.Xx_NEWLINE_xXMajor surgery or irradiation within two weeksXx_NEWLINE_xXPatients who have undergone major surgery =< 4 weeks prior to starting treatment or who have not recovered from side effects of such therapyXx_NEWLINE_xXMajor surgery or irradiation within two weeksXx_NEWLINE_xXMajor surgery within 4 weeks before the start of study therapy;Xx_NEWLINE_xXPatients must have fully recovered from all effects of surgery; patients must have had at least two weeks after minor surgery and four weeks after major surgery before starting therapy; minor procedures requiring “twilight” sedation such as endoscopies or Mediport placement may only require a 24-hour waiting period, but this must be discussed with an investigatorXx_NEWLINE_xXMajor surgery within 4 weeks or minor surgery within 2 weeks prior the first dose of study medicationXx_NEWLINE_xXMajor surgery: ?2 weeks Other protocol defined inclusion/exclusion may apply.Xx_NEWLINE_xXMajor surgery or a wound that has not fully healed within 4 weeks of enrollmentXx_NEWLINE_xXMajor surgery within 4 weeks prior to entryXx_NEWLINE_xXMajor surgery within 4 weeks of enrollmentXx_NEWLINE_xXThe participant has a history of major surgery or treatment other cancer therapy within 2-6 weeks before starting the studyXx_NEWLINE_xXMajor surgery within 4 weeks of 1st dose of study drugXx_NEWLINE_xXMajor surgery within 2 weeksXx_NEWLINE_xXMajor surgery =< 3 weeks prior to starting study drug or who have not recovered from side effects of such procedureXx_NEWLINE_xXMajor surgery within 4 weeks or minor surgery within 2 weeks prior to the first dose of study medicationXx_NEWLINE_xXMajor surgery within 4 weeks prior to C1D1Xx_NEWLINE_xXMajor surgery within 4 weeks prior to Day 1 visit.Xx_NEWLINE_xXMajor surgery within 4 weeks from cycle # 1Xx_NEWLINE_xXMajor surgery within 4 weeks of first dose of study drug.Xx_NEWLINE_xXPatients who have undergone major surgery =< 2 weeks prior to starting study drug or who have not recovered from side effects of such therapyXx_NEWLINE_xXMajor surgery within 2 weeks before cycle 1 day 1Xx_NEWLINE_xXMajor surgery, chemotherapy, radiation therapy or other cancer therapy within 3 weeks of treatment day 1Xx_NEWLINE_xXSubject has undergone major surgery for any reason, other than diagnostic surgery (ie, surgery done to obtain a biopsy for diagnosis without removal of an organ), within 4 weeks prior to Cycle 1 Day 1 of treatment in this study.Xx_NEWLINE_xXMajor surgery within 4 weeks prior to day 1 of the study or who have not recovered from prior surgeryXx_NEWLINE_xXMajor surgery within 6 weeks prior to Baseline. The subject must have recovered from surgery and be without current complications of infection or dehiscence.Xx_NEWLINE_xXAt least 2 weeks must have elapsed from any prior surgeryXx_NEWLINE_xXMajor surgery within 4 weeks of C1D1Xx_NEWLINE_xXMajor surgery, radiation therapy, or systemic anti-cancer therapy within 4 weeks of study treatment start (6 weeks for mitomycin C or nitrosoureas)Xx_NEWLINE_xXMajor surgery or radiation within 4 weeks prior to 1st doseXx_NEWLINE_xXMajor surgery or anti-cancer therapy within 4 weeks of study treatment start.Xx_NEWLINE_xXMajor surgery, other than diagnostic surgery, within 4 weeks prior to Cycle 1 Day 1, without complete recoveryXx_NEWLINE_xXPatients that have had major surgery =< 3 weeks or minor surgery (e.g. talc pleurodesis, excisional biopsy, etc) =< 1 week prior to the first day of study defined treatmentXx_NEWLINE_xXAt the time of day 1 of the study, patients must be at least 3 weeks since surgery.Xx_NEWLINE_xXPatient has undergone major surgery, other than diagnostic surgery (i.e.--surgery done to obtain a biopsy for diagnosis without removal of an organ), within 4 weeks prior to day 1 of treatment in this studyXx_NEWLINE_xXMajor surgery within 4 weeksXx_NEWLINE_xXPatient has undergone major surgery, other than diagnostic surgery (i.e. surgery done to obtain a biopsy for diagnosis without removal of an organ), within 4 weeks prior to day 1 of treatment in this studyXx_NEWLINE_xXMajor trauma or surgery w/in prior 4 weeksXx_NEWLINE_xXMajor surgery within 4 weeks of the start of study treatment, without complete recoveryXx_NEWLINE_xXMajor surgery within 2 weeks prior to study entry, except for line placement or biopsy procedure.Xx_NEWLINE_xXMajor surgery within the last 2 weeksXx_NEWLINE_xXMajor surgery other than diagnostic surgery =< 4 weeksXx_NEWLINE_xXAt least 3 weeks from major surgery with full recoveryXx_NEWLINE_xXMajor surgery within 4 weeks prior to study enrollmentXx_NEWLINE_xXRadiation and surgery within 4 weeks prior to treatment in this studyXx_NEWLINE_xXPatients who have undergone major surgery =< 4 weeks prior to starting study drug or who have not recovered from side effects of such therapyXx_NEWLINE_xXMajor surgery within 2 weeks of first dose of study drug. Patients must have recovered from the effects of any surgery performed greater than 2 weeks previously.Xx_NEWLINE_xXAt least 4 weeks have elapsed since the completion of major surgery, and the patient has fully recovered from this surgery and any post-surgical complications.Xx_NEWLINE_xXMajor surgery within 4 weeks prior to day 1Xx_NEWLINE_xXPatients who have had major surgery within 2 weeks prior to enrollment are not eligible; procedures such as placement of a central vascular catheter, or limited tumor biopsy, are not considered major surgeryXx_NEWLINE_xXSevere infection or major surgery within 4 weeks prior to randomizationXx_NEWLINE_xXMajor surgery ? 2 weeks or radiotherapy ? 4 weeks prior to planned start of study drug or patient has not recovered from major side effects.Xx_NEWLINE_xXMajor surgery within 4 weeks prior to first doseXx_NEWLINE_xXMajor surgery, excluding laparoscopy, within 4 weeks of the start of study treatment, without complete recoveryXx_NEWLINE_xXNo chemotherapy, radiotherapy, major surgery, or biologic therapy within 3 weeks of protocol treatmentXx_NEWLINE_xXLess than 3 weeks between major surgery and planned start of study treatment; major incisions must have healedXx_NEWLINE_xXPatients must be at least 4 weeks from major surgery and have fully recovered from any effects of surgery, and be free of significant detectable infection prior to registrationXx_NEWLINE_xXMajor surgery within 4 weeks of initiation of study drugXx_NEWLINE_xXMajor surgery =< 2 weeks prior to starting a study drug or who have not recovered from side effects of such therapyXx_NEWLINE_xXPrior major surgery or radiation therapy within 4 weeks of enrollment;Xx_NEWLINE_xXSubject has had major surgery within 4 weeks prior to the first study dose.Xx_NEWLINE_xXMajor surgery within 4 weeks prior to entry to the study (excluding placement of vascular access), or minor surgery within 2 weeks of entry into the study and from which the patient has not yet recoveredXx_NEWLINE_xXMajor surgery within 3 weeks before day 1Xx_NEWLINE_xXMajor surgery within 2 weeks before day 1Xx_NEWLINE_xXMajor surgery (as judged by the investigator) within 4 weeksXx_NEWLINE_xXRecent major surgery (within 6 weeks before the start of Cycle 1 Day 1), other than for diagnosisXx_NEWLINE_xXAny major surgery within 4 weeks of study randomization.Xx_NEWLINE_xXMajor surgery within 4 weeks prior to randomization.Xx_NEWLINE_xXMajor surgery within 2 weeks before the first dose of either study drugXx_NEWLINE_xXMajor surgery, radiation therapy or systemic anti-cancer therapy within 4 weeks of starting study treatmentXx_NEWLINE_xXPatients who have had major surgery within 4 weeks of enrollmentXx_NEWLINE_xXPatients who have had major surgery within 3 weeks prior to enrollment are not eligible; procedures such as placement of a central vascular catheter, or limited tumor biopsy, are not considered major surgeryXx_NEWLINE_xXMajor surgery, radiation therapy, or systemic anti-cancer therapy within 4 weeks of study treatment startXx_NEWLINE_xXMajor surgery within 4 weeks prior to first dose of ganetespibXx_NEWLINE_xXPatients who have undergone major surgery =< 3 weeks prior to starting study drug or who have not recovered from side effects of such procedureXx_NEWLINE_xXMajor surgery within 4 weeks prior to study day 1 Active infection Anti-coagulation therapy Concomitant treatment with potent CYP3A4 inducersXx_NEWLINE_xXMajor surgery, except diagnostic tumor biopsy, within 4 weeks of randomization.Xx_NEWLINE_xXSubject has had major surgery within 4 weeks prior to the first study dose.Xx_NEWLINE_xXMajor surgery within 4 weeks, or minor surgery within 2 weeks prior to day 1 of cycle 1Xx_NEWLINE_xXMajor surgery (as defined by the investigator) within 4 weeks prior to first dose of MEDI0680 (AMP-514) or still recovering from prior surgeryXx_NEWLINE_xXPatients who have received surgery are eligible if surgery is performed within 6 weeks prior to study initiation.Xx_NEWLINE_xXBe reasonably recovered from preceding major surgery as judged by the investigator or no major surgery within 4 weeks prior to the start of day 1 treatmentXx_NEWLINE_xXAnti-tumor therapy of any kind or major surgery within 4 weeks prior to Day 1.Xx_NEWLINE_xXAny major surgery within 4 weeks prior to day 1Xx_NEWLINE_xXAny of the following prior therapies for malignancy:\r\n* Systemic chemotherapy =< 4 weeks prior to registration\r\n* Radiation therapy =< 4 weeks prior to registration (exceptions noted in the prior bullet); the site of previous radiotherapy should have evidence of progressive disease if this is the only site of disease\r\n* Major surgery (i.e., laparotomy), open biopsy, or significant traumatic injury =< 4 weeks prior to registration; minor surgery =< 2 weeks prior to registration; insertion of a vascular access device is not considered major or minor surgery in this regard\r\n* Other investigational agent =< 30 days prior to study treatmentXx_NEWLINE_xXMajor surgery (within 4 weeks prior to the start of Cycle 1), other than for diagnosisXx_NEWLINE_xXMajor surgery or trauma within 4 weeksXx_NEWLINE_xXMajor surgery or significant traumatic injury within 4 weeks of randomization or patients that may require major surgery during the course of the study.Xx_NEWLINE_xXMajor surgery within 4 weeks prior to IP administrationXx_NEWLINE_xXMajor surgery =< 2 weeks prior to starting study drug or who have not recovered from side effects of such therapyXx_NEWLINE_xXMajor surgery within 4 weeks of study enrollmentXx_NEWLINE_xXFully recovered from any prior surgery and no major surgery within 4 weeks of initiating treatment, except for gamma knife which can take place within 2 weeks. Surgery for placement of vascular access devices is acceptable.Xx_NEWLINE_xXMajor surgery within 4 weeks before start of study treatment, without complete recoveryXx_NEWLINE_xXPatients who have undergone major surgery =< 4 weeks prior to starting study drug or who have not recovered from side effects of such therapyXx_NEWLINE_xXSurgery >= 4 weeks prior to registrationXx_NEWLINE_xXSubjects may not have any major surgery within 4 weeksXx_NEWLINE_xXAt least 4 weeks from prior major surgery or radiotherapyXx_NEWLINE_xXMajor surgery or significant trauma within 2 weeks prior to the first dose of study drug.Xx_NEWLINE_xXMajor surgery within 4 weeks prior to entry into the study, or a surgical incision that is not fully healedXx_NEWLINE_xXRecent major surgery within a minimum of 4 weeks prior to starting study treatment, with the exception of surgical placement for vascular accessXx_NEWLINE_xXMajor surgery within 3 weeks of starting the study or patient has not recovered from any effects of any major surgeryXx_NEWLINE_xXMajor surgery within 3 weeks of starting the study or patient has not recovered from any effects of any major surgeryXx_NEWLINE_xXPatients who have had a major surgery of significant traumatic injury within 4 weeks of start of study drug, patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia) or patients that may require major surgery during the course of the studyXx_NEWLINE_xXPatients who have had major surgery within 4 weeks of initiation of study medicationXx_NEWLINE_xXMajor surgery within four weeks of the first dose of ARQ 092Xx_NEWLINE_xXPatients who have undergone major surgery =< 2 weeks prior to starting study drug or who have not recovered from side effects of such therapyXx_NEWLINE_xXPatients must be at least 4 weeks from major surgery and have fully recovered from any effects of surgery, and be free of significant detectable infectionXx_NEWLINE_xXMajor surgery (i.e., the opening of a major body cavity, requiring the use of general anesthesia) within 4 weeks before enrollment; minor surgery (except for insertion of vascular access device) within 2 weeks before enrollment; or not yet recovered from the effects of the surgery.Xx_NEWLINE_xXPatients, who have had a major surgery or significant traumatic injury within 4 weeks of start of study drug, patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia) or patients that may require major surgery during the course of the studyXx_NEWLINE_xXMajor surgery within 4 weeks of the start of study treatment, without complete recoveryXx_NEWLINE_xXPatients who have undergone major surgery =< 4 weeks prior to starting study drug or who have not recovered from side effects of such therapyXx_NEWLINE_xXAt least 4 weeks from prior major surgery or radiotherapy.Xx_NEWLINE_xXMajor surgery, radiotherapy, chemotherapy or investigational agents within four weeks of treatment day 1Xx_NEWLINE_xXPatients who have undergone major surgery ? 4 weeks prior to starting study drug or who have not recovered from side effects of such therapyXx_NEWLINE_xXIf a patient has had major surgery, the patient must be longer than four weeks post surgery and must have recovered from all toxicity prior to beginning protocol studyXx_NEWLINE_xXMajor surgery or a wound that has not fully healed =< 4 weeks prior to registrationXx_NEWLINE_xXMajor surgery or a wound that has not fully healed within 4 weeks of treatmentXx_NEWLINE_xXA history of gastrointestinal malabsorption or having undergone surgery requiring gastrointestinal anastomoses within four weeks of starting therapy or who have not recovered from major surgery within three weeks of starting therapyXx_NEWLINE_xXPatients who have undergone any major surgery within 2 weeks prior to starting study drug or who have not adequately recovered from previous surgeryXx_NEWLINE_xXRadiotherapy or major surgery within 4 weeksXx_NEWLINE_xXMajor surgery within four weeks before cycle 1, day 1Xx_NEWLINE_xXMajor surgery within preceding 8 weeksXx_NEWLINE_xXPatients who have undergone major surgery =< 3 weeks prior to starting study drug or who have not recovered from side effects of such procedureXx_NEWLINE_xXAny non-cranial surgery within 4 weeks of study registration; must be recovered and fully healed from any prior surgeryXx_NEWLINE_xXMajor surgery within the past 2 weeks.Xx_NEWLINE_xXHave reasonably recovered from preceding major surgery as judged by the investigator or have had no major surgery within 4 weeks prior to Day 1 treatment.Xx_NEWLINE_xXMajor surgery within 4 weeks prior to the start of the study;Xx_NEWLINE_xXHas not recovered from major surgery prior to starting study therapyXx_NEWLINE_xXMajor surgery performed within 3 weeks prior to the first dose of study drugs or scheduled for major surgery during the studyXx_NEWLINE_xXMajor surgery or radiation therapy within 4 weeks from start of treatmentXx_NEWLINE_xXMajor surgery or a wound that has not fully healed within 4 weeks of starting ibrutinibXx_NEWLINE_xXMajor surgery less than 4 weeks before the start of the studyXx_NEWLINE_xXPHASE 1 & 2: Identified within two weeks of surgeryXx_NEWLINE_xX>= 4 weeks since last major surgery and fully recoveredXx_NEWLINE_xXNo major surgery within 2 weeks prior to signing of study enrollmentXx_NEWLINE_xXRecovered from major surgery within the last 6 monthsXx_NEWLINE_xXParticipant had recent surgery (within two weeks)Xx_NEWLINE_xXMajor surgery within 1 month of starting study program and patients must have recovered from any effects of major surgeryXx_NEWLINE_xXMajor surgery within 4 weeks or till recovery to baseline functioning (per patient) whichever is shorterXx_NEWLINE_xXPrior major surgery within 4 weeks of starting study drug administrationXx_NEWLINE_xXMajor surgery, significant trauma, wide-field radiotherapy, or therapy with monoclonal antibodies within 4 weeks before the first dose of study drugXx_NEWLINE_xXTrauma or major surgery within 4 weeks of first study drug administrationXx_NEWLINE_xXMajor surgery within 4 weeks of first dose of study drugXx_NEWLINE_xXMajor surgery within 4 weeks of first dose of study drugXx_NEWLINE_xXThe patient must be recovered from a prior major surgery; the major surgery must be performed at least 4 weeks prior to consent dateXx_NEWLINE_xXMajor surgery within four weeks before consent dateXx_NEWLINE_xXPatient underwent major systemic surgery =< 2 weeks prior to starting the trial treatment or who has not recovered from the side effects of such surgery, or who plan to have surgery within 2 weeks of the first dose of the study drugXx_NEWLINE_xXMajor surgery within the past 2 weeksXx_NEWLINE_xXMajor surgery within two weeks of study registration of which the patient has not recoveredXx_NEWLINE_xXPatients who have had major surgery within 4 weeks of initiation of study medicationXx_NEWLINE_xXMajor surgery or radiation treatment within 3 monthsXx_NEWLINE_xXEXCLUSION CRITERIA (PRIOR TO IBRUTINIB ADMINISTRATION): Major surgery within 4 weeks of first dose of study drugXx_NEWLINE_xXParticipants with acute intercurrent illness or those who had major surgery within the preceding 4 weeks unless they have fully recoveredXx_NEWLINE_xXAny major surgery within the last four weeks.Xx_NEWLINE_xXSubjects who have undergone major surgery ? 2 weeks prior to starting study drugs.Xx_NEWLINE_xXMajor surgery within 2 weeksXx_NEWLINE_xXSurgery within 4 weeks prior to first doseXx_NEWLINE_xXMajor surgery within 4 weeks or incompletely healed surgical incision before starting study therapyXx_NEWLINE_xXPatient must not have undergone major surgery or radiotherapy to the pelvis or abdomen within previous 4 weeksXx_NEWLINE_xXNo surgery in the last 2 weeks prior to study enrollmentXx_NEWLINE_xXMajor surgery (excluding placement of vascular access) within 4 weeks of the first dose of study drug treatmentXx_NEWLINE_xXMajor surgery within 4 weeks prior to first dose of study treatment.Xx_NEWLINE_xXSubjects must not have had major surgery as determined by the PI within 4 weeks before the first dose of investigational agent.Xx_NEWLINE_xXMajor surgery within 4 weeks prior to C1D1.Xx_NEWLINE_xXHad major surgery within 4 weeks before study drug treatmentXx_NEWLINE_xXMajor surgery within 4 weeks of first dose of study drugXx_NEWLINE_xXHistory of severe trauma or major surgery within 4 weeks prior to the initiation of study drug administration.Xx_NEWLINE_xXHas had chemotherapy, radiation, biological cancer therapy or major surgery within 4 weeks prior to the first dose of study treatmentXx_NEWLINE_xXMajor surgery within 4 weeks of the start of study treatment, without complete recoveryXx_NEWLINE_xXMajor surgery or other loco regional treatment within 4 weeks before the first dose of study drug or radionuclide treatment within 8 weeksXx_NEWLINE_xXA minimum of 4 weeks from any major surgery prior to enrollment; coincident standard of care surgery with the research biopsy is permitted during the studyXx_NEWLINE_xXMajor surgery other than diagnostic surgery =< 4 weeks prior to registrationXx_NEWLINE_xXMajor surgery within 4 weeksXx_NEWLINE_xXMajor surgery within 4 weeks prior to entry to the study (excluding placement of vascular access), or minor surgery within 2 weeks of entry into the study.Xx_NEWLINE_xXMajor surgery in the past 8 weeks (Arms 1 and 4)Xx_NEWLINE_xXNo major surgery within 4 weeks of first dose of SGI-110.Xx_NEWLINE_xXMajor surgery, significant trauma, wide-field radiotherapy, or therapy with monoclonal antibodies within 4 weeks before the first dose of study drugXx_NEWLINE_xXHistory of major surgery within 4 weeks prior to first dose on this studyXx_NEWLINE_xX